Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8752MR)

This product GTTS-WQ8752MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8752MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ765MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ14162MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ2177MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ3218MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ13374MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ5147MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ233MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ7279MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FP3 protein
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW